Positions

Overview

  • Harry Erba, M.D., Ph.D., is a Professor of Medicine, Director of the UAB Hematologic Malignancy Program and Associate Director for Clinical Research at the UAB Comprehensive Cancer Center.

    Dr. Erba received his M.D. and Ph.D. degrees from Stanford University. He did his internship and residency in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School. Following a fellowship in hematology/oncology at the same institution, he joined the Harvard Medical School faculty for 3 years until he moved to the University of Michigan at Ann Arbor where he rose to the rank of Associate Professor.Over the past decade Dr. Erba has become a highly respected leader in the field of hematologic malignancies, especially with respect to the assessment of novel therapies in acute myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndromes. He is an executive officer of SWOG (formerly, Southwest Oncology Group), working closely with the leadership of the SWOG leukemia, lymphoma, myeloma and bone marrow transplant committees. He is an active member in the SWOG leukemia committee and will become chair in the next month.

    He has served on the National Comprehensive Cancer Network (NCCN) Practice Guidelines Committees for acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and myeloid growth factors. He was given Special Recognition and Appointment to the NCCN Board of Producers in 2007 and 2008. He has been involved in numerous clinical trials in hematologic malignancies, led many national trials as a chair or co-chair, and played major roles in the development of several new drugs. He was named Teacher of the Year in the Division of Hematology/Oncology for four consecutive years at the University of Michigan. In 2004 he was given the Outstanding Clinician Award by the Dean of the University of Michigan Medical School, and this year was appointed as an inaugural member of the League of Clinical Excellence at the University of Michigan.

    His work has been published in high-impact journals such as Nature, Cell, Journal of Clinical Oncology, Blood, Cancer Research and British Journal of Haematology. In addition to 47 peer-reviewed publications, he has authored five book chapters and has lectured extensively in the US, Canada, Europe and Japan.
  • Principal Investigator On

  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2019 - 2025
  • UAB 1640-Phase II Trial of Vosaroxin in Combination with Infusional Cytarabine in Patients with Untreated AML  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2016 - 2019
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2018 - 2019
  • Private Grant  awarded by AMGEN, INC. 2018 - 2019
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2016 - 2019
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2015 - 2018
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2016 - 2018
  • SWOG Network Group Operations Center of the NCTN  awarded by Oregon Health & Science University 2014 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2016 - 2018
  • Southwest Oncology Group Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP 2013 - 2018
  • Private Grant  awarded by IMMUNOGEN, INC. 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2016 - 2018
  • Private Grant  awarded by AMGEN, INC. 2014 - 2018
  • Southwest Oncology Group Clinical Trials Initiative Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP 2013 - 2018
  • Private Grant  awarded by CELATOR PHARMACEUTICALS, INC. 2012 - 2017
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2017
  • Private Grant  awarded by Janssen 2016 - 2017
  • Private Grant  awarded by AGIOS 2015 - 2017
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2017
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by IMMUNOGEN, INC. 2016 - 2017
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015 - 2017
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2017
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2014 - 2016
  • Active - NCI Clinical Trial Reporting Program - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2013 - 2014
  • SWOG Treatment Grant (U10 CA032102)  awarded by Oregon Health & Science University 2013 - 2014
  • Southwest Oncology Group Operations Office Grant  awarded by University of Michigan 2012 - 2013
  • Investigator On

  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Private Grant  awarded by ABBVIE INC 2018 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2019
  • Private Grant  awarded by AMGEN, INC. 2018 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant - Adiministrative Core  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2019
  • Private Grant  awarded by Gilead Sciences 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by Genentech 2013 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Private Grant  awarded by GlaxoSmithKline 2013 - 2016
  • Private Grant  awarded by MedImmune 2014 - 2016
  • Private Grant  awarded by ELI LILLY AND COMPANY 2013 - 2016
  • Active - Senior Leadership - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015 - 2016
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2014 - 2016
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2013 - 2015
  • Private Grant  awarded by CYCLACEL LTD 2014 - 2015
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2013 - 2015
  • Private Grant  awarded by ABBVIE INC 2013 - 2014
  • Private Grant  awarded by SPECTRUM PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2014
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2013
  • Full Name

  • Harry Erba